Skip to main content
. Author manuscript; available in PMC: 2020 Sep 17.
Published in final edited form as: Mol Cancer Ther. 2016 Jun 20;15(9):2251–2258. doi: 10.1158/1535-7163.MCT-15-0908

Table 3.

Intratumoral gene expression by treatment

Prior treatment
Posttreatment
Change (post-prior)
Gene n Median (min–max) n Median (min–max) n Median (min–max) Pa
TS 38 3.16 (0.53–9.57) 39 3.64 (0.67–11.30) 34 0.38 (−2.33–7.25) 0.10
DPD 32 0.58 (0.14–1.87) 33 0.68 (0.16–2.71) 26 0.12 (−0.61–1.04) 0.097
EGFR/HER1 37 1.59 (0.51–87.84) 37 1.73 (0.10–89.64) 32 0.15 (−1.88–41.89) 0.10
HER2 33 0.04 (0.01–0.49) 34 0.06 (0.01–1.87) 28 0.01 (−0.29–1.61) 0.26
HER3 37 4.51 (1.25–43.61) 40 6.18 (0.89–12.86) 33 0.87 (−36.31–8.18) 0.38
a

Based on the Wilcoxon signed rank test.